Genomenon's Curation and Global Distribution of Variant Data Reduces Barriers to Genetic Diagnosis ANN ARBOR, Mich., March 10, 2026 /PRNewswire/ -- Genomenon today announced a strategic sponsorship ...

MindImmune today announced a transformative $5 million award from the Alzheimer's Drug Discovery Foundation (ADDF) to accelerate development of its lead therapeutic candidate, MITI-101 ? a ...

Sangamo Therapeutics has initiated a rolling Biologics License Application (BLA) submission with the U.S. Food and Drug Administration for its investigational g ...

Italy’s Chiesi Group and Israel’s Protalix BioTherapeutics have announced that the European Commission (EC) has approved the 2mg/kg every-4-weeks (E4W) dosing regimen for Elfabrio (pegunigalsidase ...

European Commission approval enables 2 mg/kg Q4W pegunigalsidase alfa for stable, ERT-treated adults, extending infusion intervals from Q2W to Q4W to lessen cumulative treatment burden. Evidence ...

Protalix Biotherapeutics Inc (NYSE-A:PLX, FRA:PBDA) announced that the European Commission has approved a new dosing regimen ...

Approved dosing regimen reduces the burden for eligible patients, their families, and the broader healthcare system by ...

Data support potential of isaralgagene civaparvovec as a one-time, well tolerated and durable Fabry disease gene therapy to provide meaningful, multi-organ clinical benefits that could fundamentally ...

Data support potential of isaralgagene civaparvovec as a one-time, well tolerated and durable Fabry disease gene therapy to provide meaningful, ...

This press release is intended for US audiences for transparency relative to global news for the Fabry community. This dosing regimen for ...

Detailed price information for Acumen Pharmaceuticals Inc (ABOS-Q) from The Globe and Mail including charting and trades.